XTX Topco Ltd Has $28,000 Holdings in Nuvation Bio Inc. (NYSE:NUVB)

XTX Topco Ltd lessened its stake in Nuvation Bio Inc. (NYSE:NUVB - Free Report) by 92.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,585 shares of the company's stock after selling 121,444 shares during the period. XTX Topco Ltd's holdings in Nuvation Bio were worth $28,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. LPL Financial LLC increased its holdings in shares of Nuvation Bio by 27.0% during the fourth quarter. LPL Financial LLC now owns 31,348 shares of the company's stock valued at $83,000 after acquiring an additional 6,673 shares in the last quarter. Invesco Ltd. lifted its stake in Nuvation Bio by 2.3% in the 4th quarter. Invesco Ltd. now owns 330,388 shares of the company's stock valued at $879,000 after buying an additional 7,344 shares in the last quarter. Cerity Partners LLC acquired a new stake in Nuvation Bio during the 4th quarter worth $31,000. Bank of New York Mellon Corp grew its position in shares of Nuvation Bio by 2.8% in the fourth quarter. Bank of New York Mellon Corp now owns 518,575 shares of the company's stock valued at $1,379,000 after purchasing an additional 14,203 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its stake in Nuvation Bio by 15,183.7% during the fourth quarter. Russell Investments Group Ltd. now owns 15,895 shares of the company's stock worth $42,000 after purchasing an additional 15,791 shares during the period. Institutional investors own 61.67% of the company's stock.

Wall Street Analyst Weigh In

NUVB has been the subject of a number of research analyst reports. Jones Trading initiated coverage on Nuvation Bio in a report on Wednesday, March 12th. They set a "buy" rating and a $10.00 target price for the company. Wedbush reaffirmed an "outperform" rating and set a $5.00 price objective on shares of Nuvation Bio in a research report on Thursday, March 27th. Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 price target (up from $6.00) on shares of Nuvation Bio in a research note on Tuesday, January 7th. Citigroup started coverage on shares of Nuvation Bio in a research report on Wednesday, April 23rd. They set an "outperform" rating for the company. Finally, JMP Securities started coverage on Nuvation Bio in a research note on Wednesday, April 23rd. They set a "market outperform" rating and a $6.00 price target for the company. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $7.83.

Nuvation Bio Price Performance

Shares of NYSE:NUVB traded down $0.06 on Wednesday, reaching $2.03. 3,807,077 shares of the company traded hands, compared to its average volume of 2,163,488. The company's 50 day moving average is $1.97 and its 200-day moving average is $2.36. The stock has a market capitalization of $687.52 million, a PE ratio of -0.94 and a beta of 1.42. Nuvation Bio Inc. has a fifty-two week low of $1.54 and a fifty-two week high of $3.97.

Nuvation Bio (NYSE:NUVB - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.16) EPS for the quarter, meeting the consensus estimate of ($0.16). As a group, analysts expect that Nuvation Bio Inc. will post -0.36 EPS for the current year.

Insider Buying and Selling at Nuvation Bio

In related news, insider Dongfang Liu sold 20,000 shares of the company's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $2.50, for a total value of $50,000.00. Following the completion of the sale, the insider now owns 12,000 shares in the company, valued at $30,000. This represents a 62.50 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO David Hung purchased 300,000 shares of the business's stock in a transaction on Monday, April 7th. The stock was bought at an average cost of $1.62 per share, for a total transaction of $486,000.00. Following the purchase, the chief executive officer now owns 58,781,054 shares of the company's stock, valued at approximately $95,225,307.48. This represents a 0.51 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 29.93% of the company's stock.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.